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Abstract
Background: Myasthenia gravis (MG) is an autoimmune dis-
order affecting neuromuscular transmission. Exacerbations 
may involve increasing bulbar weakness and/or sudden re-
spiratory failure, both of which can be critically disabling. 
Management of MG exacerbations includes plasma ex-
change and intravenous immunoglobulin (IVIG); they are 
equally effective, but patients experience fewer side effects 
with IVIG. The objective of this study was to assess the effi-
cacy and safety of immune globulin caprylate/chromatogra-
phy purified (IGIV-C) in subjects with MG exacerbations. 
Methods: This prospective, open-label, non-controlled 28-
day clinical trial was conducted in adults with MG Founda-
tion of America class IVb or V status. Subjects received IGIV-C 
2 g/kg over 2 consecutive days (1 g/kg/day) and were as-
sessed for efficacy/safety on Days 7, 14, 21, and 28. The pri-
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mary efficacy endpoint was the change from Baseline in 
quantitative MG (QMG) score to Day 14. Secondary end-
points of clinical response, Baseline to Day 14, included at 
least a 3-point decrease in QMG and MG Composite and a 
2-point decrease in MG-activities of daily living (MG-ADL). 
Results: Forty-nine subjects enrolled. The change in QMG 
score at Day 14 was significant (p < 0.001) in the Evaluable 
(–6.4, n = 43) and Safety (–6.7, n = 49) populations. Among 
evaluable subjects, Day 14 response rates were 77, 86, and 
88% for QMG, MG Composite, and MG-ADL, respectively. 
IGIV-C showed good tolerability with no serious adverse 
events. Conclusions: The results of this study show that IGIV-
C was effective, safe, and well tolerated in the treatment of 
MG exacerbations. © 2019 S. Karger AG, Basel
Introduction
Myasthenia gravis (MG) is an autoimmune disease 
mediated by the presence of pathogenic antibodies against 
components of the postsynaptic striated muscle mem-
brane of the neuromuscular junction. In most cases, the 
autoantibodies are against the acetylcholine receptor 
(AChR); other targets, such as muscle-specific kinase 
(MuSK) and lipoprotein-related protein 4, have also been 
described [1, 2]. MG is characterized by fluctuating mus-
cle weakness that may be fatigable; it worsens with repet-
itive physical exertion and improves with rest. In 80–85% 
of patients, MG evolves from only ocular symptoms (pto-
sis and diplopia) at initial presentation to generalized MG 
with weakness affecting other muscle groups [1]. In some 
patients, substantial worsening of generalized weakness – 
especially if involving bulbar muscles, triggered by infec-
tion, surgery, stress, medication, or other factors – may 
lead to impending or manifest MG exacerbations. Acute 
episodes of MG exacerbations with respiratory muscle 
and severe swallowing disorders occur in 20–30% of pa-
tients [1, 2].
First-line treatment of patients with MG involves cho-
linesterase inhibitors augmented by corticosteroid (CS) 
therapy and other immunosuppressants and immuno-
modulators to control worsening generalized weakness 
[3]. Treatment of severe MG exacerbations with bulbar 
and/or respiratory involvement typically includes intra-
venous immune globulin (IVIG) and plasma exchange 
(PLEX). According to the International Consensus Guid-
ance for management of MG [4], IVIG and PLEX are 
mainstays of management in myasthenic crisis, and the 
use of IVIG and PLEX in this setting is supported by a 
range of clinical studies [5–10]. A relatively rapid onset of 
action makes these agents useful for patients with wors-
ening or life-threatening MG symptoms and, although 
they are equally effective, IVIG is associated with fewer 
side effects than PLEX [11, 12], and it can be used in pa-
tients with a history of non-response or contraindications 
to PLEX [13]. These clinical benefits provide the rationale 
for recommendations of the use of IVIG for acute exac-
erbations of MG in multiple guidelines, including the 
American Academy of Neurology, the European Federa-
tion of Neurological Societies, the American Academy of 
Allergy, Asthma and Immunology [14], and the Associa-
tion of British Neurologists, among others [4, 15–17]. In 
most patients, IVIG is administered at doses of 2 g/kg of 
body weight over 2 to 5 days. Its exact mechanism of ac-
tion of IVIG is unclear but may include blockade of Fc 
receptors on macrophages, reduced complement activa-
tion, and diminished production of antibodies and cyto-
kines [18]. 
Immune Globulin (Human), 10% Caprylate/Chroma-
tography Purified ([IGIV-C] Gamunex®-C, Grifols Inc., 
Clayton, NC, USA) is a sterile solution of human immune 
globulin (100 mg/mL) purified from human plasma in-
tended for IV administration. In the European Union, 
IGIV-C received marketing authorization for primary 
humoral immunodeficiency, primary immune thrombo-
cytopenia, secondary immune deficiencies, Guillain-Bar-
ré syndrome, and Kawasaki disease in 2006 and for chron-
ic inflammatory demyelinating polyneuropathy in 2009; 
worldwide, IGIV-C is currently approved in 55 countries. 
Clinical trial and post-marketing experience have dem-
onstrated that IGIV-C is safe and well-tolerated for li-
censed indications requiring a 2 g/kg dose. The objective 
of the present study was to evaluate the efficacy of an IV 
infusion of IGIV-C (2 g/kg administered over 2 consecu-
tive days at a dose of 1 g/kg per day) in subjects with MG 
exacerbations.
Methods
The study protocol was approved by Institutional Review 
Boards/Independent Ethics Committees/Research Ethics Boards 
at all participating institutions (see Supporting Information for 
full listing) and by regulatory authorities. It was registered at Clin-
icalTrials.gov (NCT02413580) and European Clinical Trials Reg-
ister (EudraCT number 2013-005098-28). All subjects provided 
written informed consent, and the investigators ensured that all 
study-related activities were conducted in full conformance with 
appropriate local laws, regulations, International Conference on 
Harmonisation Good Clinical Practice, and the Declaration of 
Helsinki.
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Subjects
To be eligible, subjects had to be aged ≥18 years and have MG 
exacerbations not attributable to an infection or change in medica-
tion (defined as worsening of MG symptoms to MG Foundation of 
America (MGFA) class IVb or V) while on long-term (≥8 weeks) CS 
MG treatment. Subjects were excluded if they had received either 
IVIG or PLEX within 30 days, had modified CS dosage within the 
last 2 weeks, were known to be positive for antibodies against MuSK, 
or had MG exacerbations attributable to change in medication or 
infection (manifested by fever, positive blood culture, leukocytosis, 
pulmonary infiltrate on X-ray, and/or per investigator’s judgment).
Study Design 
This multicenter, prospective, open-label, non-controlled 
study assessing the efficacy and safety of IGIV-C in subjects with 
MG exacerbations was conducted at 15 enrolling centers in 10 
countries (Latvia, Belgium, Czech Republic, Poland, Romania, 
Russian Federation, Argentina, France, South Africa, Canada). A 
single-dose course of IGIV-C was followed by 28 days of post-in-
fusion assessments. The total duration of study participation for 
each subject was up to 28 ± 2 days.
Treatment
All subjects received an infusion of IGIV-C 2 g/kg body weight 
administered immediately after Baseline (Day 0) assessments were 
completed as a 1 g/kg/day dose over 2 consecutive days. 
Assessments
Baseline assessments included Quantitative MG (QMG), MG 
Composite, MG-Activities of Daily Living (ADL), local laboratory 
testing (hematology, chemistry, hemolysis monitoring), and 
AChR and MuSK antibody testing. QMG, MG Composite, and 
MG-ADL were performed on Days 7, 14, 21, and 28. AChR anti-
body testing was done at Days 14 and 28, and hemolysis labora-
tory assessments were repeated between 8 and 24 h after the second 
day of IGIV-C infusion and also on Days 7 and 28 (i.e., direct an-
tiglobulin testing [DAT], serum/plasma free hemoglobin, hapto-
globin, lactate dehydrogenase, fractionated bilirubin, examination 
of blood smear for spherocytes, absolute reticulocyte count, and 
assessment for hemoglobinuria). 
Changes to routine MG therapy (e.g., CS, cholinesterase in-
hibitors or other immunosuppressants) were not permitted until 
Day 14 after the primary efficacy assessment, unless necessary for 
safety reasons per the investigator’s assessment. Additionally cho-
linesterase inhibitors were to be held 12 h prior to QMG assess-
ment with the exception of the Baseline visit.
Outcomes
Efficacy
The primary efficacy outcome measure was changed in QMG 
score from Baseline to Day 14, similar to precedent studies [11, 15, 
19–22]. The 3 secondary efficacy endpoints were percentage of sub-
jects with a clinical improvement from Baseline to Day 14 defined 
as a categorical response: for QMG at least a 3-point decrease [23], 
for MG Composite at least a 3-point decrease [24], and for MG-
ADL at least a 2-point decrease [25]. Exploratory efficacy endpoints 
included change from baseline in QMG, MG Composite, and MG-
ADL at other time points relative to Baseline, and percentage of 
subjects with clinical improvement (thresholds defined above) in 
QMG, MG Composite, and MG-ADL at all other time points.
Safety
Safety outcomes included adverse events, suspected adverse 
drug reactions, adverse reactions, serious adverse events 
(AEs), vital signs, physical assessments, blood biochemistry 
and hematology, thromboembolic events risk, and hemolysis 
detection.
Statistical Analysis
Sample size calculations were derived from the study by 
 Zinman et al. [19] indicating that the standard deviation (SD) for 
change from baseline to Day 14 in QMG score was in the range of 
2.74–3.48. Considering the international scope of this study, an SD 
of 6.0 for QMG score change from baseline to Day 14 was assumed. 
Therefore, with a 2-sided test, 33 subjects were needed to have 90% 
power to detect a clinically significant improvement of 3.5 points 
in mean change in QMG [19]. Fifty subjects were planned to be 
enrolled in order to assure that a study population of 33 subjects 
would be evaluable for efficacy.
The Evaluable population consisted of subjects who re-
ceived  2 g/kg IGIV-C over 2 consecutive days and had valid 
Baseline and Day 14 QMG assessments and no major/criti-
cal  protocol deviations impacting primary efficacy analysis. 
The  Safety population included all subjects who received any 
IGIV-C.
For the primary efficacy outcome, a paired t test (compari-
son pre- and post-) was used to test for treatment effect, and 
the 95% confidence interval (CI) was calculated. The hypothesis 
was to test the null hypothesis H0 (µd = 0) versus the alternative 
hypothesis Ha (µd ≠ 0), where µd was the mean change from 
baseline to Day 14. If the assumptions for the parametric test 
were not met, the nonparametric test (Wilcoxon signed rank 
test) was used. The Shapiro-Wilk test was used to test the nor-
mality. 
Summary statistics was provided for the percentage of sub-
jects achieving the clinical response threshold at Day 14 (i.e., 
3  secondary efficacy endpoints) and for exploratory efficacy 
endpoints that were categorical for all other time points. 
For QMG, MG Composite, and MG-ADL as continuous vari-
ables, a paired t test or Wilcoxon signed rank test was used 
for  testing the treatment effect (if applicable) at different vis-
its  for  change from baseline in QMG, MG Composite, and 
 MG-ADL. 
All descriptive statistics was calculated in SAS® version 9.4 or 
higher. All statistical inferences on efficacy data analyses were test-
ed 2-sided with α = 0.05, if applicable. 
Results
Forty-nine subjects were recruited and participated in 
the study from June 1, 2015 through April 17, 2018. All 
49 enrolled subjects were analyzed for safety, and 43 were 
evaluated for efficacy. Of the 6 subjects excluded from the 
Evaluable population, 4 received IGIV-C on the first infu-
sion day only with none (n = 3) or very little (n = 1) in-
fused on the second dosing day due to non-serious AEs; 
2 violated inclusion criteria either due to clinical presen-
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tation inconsistent with MG exacerbation (QMG = 6) or 
fewer than 8 weeks CS MG treatment. Subject disposition 
in shown in Figure 1.
Demographics and Baseline Characteristics
Demographic and baseline disease characteristics are 
summarized in Table 1. Subjects were predominantly fe-
male (69.4%) and White (89.8%), with a median age of 
47.0 years and median time since MG diagnosis of 5.4 
years. No subjects were MuSK-antibody positive. Details 
of historical testing establishing the diagnosis of MG are 
included in Table 1.
Efficacy
At Baseline, median QMG, MG Composite, and MG-
ADL scores were 22, 30, and 14 points, respectively, indi-
cating significant MG-related weakness. For the primary 
efficacy endpoint in the Evaluable population, there was a 
significant decrease in mean ± SD QMG from Baseline to 
Day 14 (–6.4 ± 5.15, p < 0.001, 95% CI –7.957 to –4.787); 
results in the Safety population were comparable. A sig-
nificant decrease in QMG was evident at Day 7 and be-
came increasingly pronounced at Day 21. Efficacy data are 
summarized in Table 2 for all efficacy scales analyzed as 
continuous variables. Figure 2 provides illustrations of 
mean change from baseline for QMG, MG Composite, 
and MG-ADL scores for the Evaluable population at all 
study time points.
Of the 43 subjects assessed on the secondary efficacy 
endpoints, 33 (76.7%) achieved a clinical response as 
measured by QMG, 37 (86.0%) surpassed the response 
threshold on the MG Composite, and 38 (88.4%) achieved 
a response on the MG-ADL. Categorical responses at all 
time points are illustrated in Figure 3. 
In the exploratory efficacy analyses, the mean QMG 
changes from baseline were –4.7, –6.4, –7.9, and –7.8 at 
Days 7, 14, 21, and 28, respectively. The mean changes 
from baseline in MG Composite score were –7.8, –12.1, 
–13.6, and –13.7 at Days 7, 14, 21, and 28, respectively. 
For MG-ADL, the respective mean changes from base-
line were –4.2, –6.2, –7.0, and –7.0 at Days 7, 14, 21, and 
28. Similar results for all exploratory analyses of effi-
cacy parameters were observed in the Safety population.
For all 3 efficacy parameters, response was robust at 
Day 7, improved at Days 14 and 21, and remained evident 
at the last time point on Day 28. Group mean and median 
MG Composite and MG-ADL scores were substantially 
reduced to approximately 50–60% of their entry value by 
Day 14 in Evaluable and Safety populations, and group 
median values were half of entry median scores at Day 28.
Following IGIV-C administration, AChR antibody 
levels decreased; no subjects became negative for anti-
AChR (data not shown).
Safety
Of the 49 subjects in the Safety population, 39 
(79.6%) reported treatment-emergent AEs (TEAEs). 
The most frequent TEAEs in these subjects were head-
ache 19 (38.8%), pyrexia 8 (16.3%), urticaria 4 (8.2%), 
influenza-like illness 3 (6.1%), rash 3 (6.1%), and vom-
iting 3 (6.1%). Most TEAEs were mild or moderate. 
There were no serious AEs and no thromboembolic 
events. Three subjects discontinued study prematurely 
and did not receive the second day of IGIV-C infusion 
due to mild or moderate non-serious AEs that fully re-
solved within 1 day (rash pruritic n = 1 subject, urti-
caria n = 1 subject, and 1 subject with hypersensitivity 
manifesting as facial hyperemia, back pain, headache, 
myalgia, and pyrexia). A summary of TEAEs is provid-
ed in Table 3. 
Routine clinical laboratory parameters (chemistry, he-
matology, and urinalysis) and vital signs data showed no 
consistent treatment-emergent pattern of abnormality. 
Twenty-one subjects (42.9%) had a positive DAT after 
IGIV-C administration, but these results were transient 
in some cases and not sustained. Five subjects (10.2%) 
Valid for evaluable population
(n = 43)
Baseline
1st dose of IGIV-C 1 g/kg
Day 1
2nd dose of IGIV-C 1 g/kg
Completed
(n = 46)
Excluded (n = 6)
– AE (3)
– Inclusion criteria (2)
– Not treateda (1)
Enrolled
(n = 49)
Signed informed consent
(n = 49)
Valid for safety population
(n = 49)
Fig. 1. Subject disposition. AE, adverse event; IGIV-C, immune 
globulin caprylate/chromatography purified. a Did not receive a 
full dose on Day 1 due to AEs of vomiting and nausea.
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fulfilled a prospectively defined hemolysis algorithm (i.e., 
positive DAT with ≥1 g/dL decreased hemoglobin and 2 
additional laboratory markers of potential hemolysis). 
For 3 of these 5 subjects, anemia (hemoglobin < lower 
normal limit) resulted in nadir of values 9.62, 11.8, and 
12.0 g/dL, corresponding to decreases of 2.6, 3.3, and 1.6 
g/dL from prior visit. Two subjects had TEAEs of anemia 
considered potentially related to IGIV-C of mild inten-
sity with full recovery.
Discussion
This multicenter, prospective, open-label, non-con-
trolled clinical trial was conducted to assess the efficacy 
and safety of IGIV-C in subjects with MG exacerbations 
producing significant disability (MGFA IVb or V). Re-
sults show that clinically meaningful improvement was 
observed for all efficacy parameters. Specifically, for the 
primary endpoint, there was a significant decrease in 
QMG scores from Baseline to Day 14 in the Evaluable 
population. Secondary endpoints all showed an efficacy 
benefit in the majority of Evaluable subjects (≥76.7% re-
sponders at Day 14). Among the exploratory endpoints, 
a profound decrease in MG Composite and MG-ADL 
total score was shown by the 50–60% reduction in group 
median entry values by Day 14. There were no safety is-
sues or specific laboratory trends of interest related to 
study drug infusion, except for positive DAT with revers-
ible decreased hemoglobin in a few subjects. In this study, 
therefore, IGIV-C was effective, safe, and well tolerated 
in the treatment of patients with MG exacerbations.
These findings appear robust in the context of the 
literature data for IVIG in MG worsening and MG ex-
acerbations [11, 15, 19–22]. For example, Zinman et al 
[19, 21] evaluated IGIV-C 2 g/kg versus placebo in 51 
Table 1. Subject demographics and disease characteristicsa
Gender, n (%)
Female 34 (69.4)
Male 15 (30.6)
Age, years
Mean ± SD 47.3±15.22
Median (range) 47.0 (18–82)
Weight, kg
Mean ± SD 71.9±16.01
Median (range) 70.0 (40.0–104.0)
Race, n (%)
White 44 (89.8)
Black or African American 2 (4.1)
Asian 1 (2.0)
American Indian or Alaska Native 1 (2.0)
Unknown 1 (2.0)
MGFA classification at enrollment, n (%)
IVb 49 (100)
V 0 (0)
Time since initial MG diagnosis, years
Mean ± SD 7.85±8.90
Median (range) 5.36 (0.15–39.18)
Historical test performed to confirm MG diagnosisb, n (%)
Edrophonium chloride test or equivalent 15 (30.6)
Acetylcholine receptor antibody test positive 29 (59.2)
Single-fiber EMG or electrodiagnostic testc diagnostic/consistent with MG 39 (79.6)
Time since last MG exacerbation, years
Mean ± SD (n = 44) 1.37±2.2128
Median (range) (n = 44) 0.26 (0.01–11.18)
a (n = 49) subjects unless otherwise specified.
b Diagnostic options are not mutually exclusive.
c Such as repetitive nerve stimulation.
MG, myasthenia gravis; MGFA, MG Foundation of America; EMG, electromyography.
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subjects and showed a mean change in QMG at Day 14 
of –2.54 in the IGIV-C group versus –0.89 for placebo 
(p = 0.047); a more pronounced treatment effect was 
observed in subjects with QMG scores > 10.5 prior to 
treatment with IGIV (–4.10 vs. –0.71, p = 0.010). Other 
work comparing 2 g/kg IGIV-C with PLEX in 84 sub-
jects with QMG scores > 10.5 at study entry found mean 
± SD changes from baseline in QMG score of –3.2 ± 4.1 
points for IGIV-C and –4.7 ± 4.9 points for PLEX (p = 
0.13) at Day 14, providing evidence that IVIG and 
Table 2. Analysis of change in QMG, MG composite, MG-ADL (Evaluable population, n = 43)
Measure Day Baseline score Change from Baseline p valuea 95% CI
of mean changemean ± SD median 
(min – max)
mean ± SD median
(min – max)
QMG 0 22.0±4.60 22.0 (14 to 33) – – – –
7 17.5±5.17 17.0 (1 to 29) –4.7±4.58 –4.0 (–21 to –4) <0.001 –
14 15.6±5.14 16.0 (4 to 27) –6.4±5.15 –6.0 (–15 to –8) <0.001 –7.957 to –4.787
21 14.1±4.73 15.0 (0 to 23) –7.9±5.78 –8.0 (–22 to –4) <0.001 –9.686 to –6.128
28 14.2±5.22 15.0 (0 to 24) –7.8±5.71 –8.0 (–22 to –4) <0.001 –9.572 to –6.056
MG composite 0 28.9±6.80 30.0 (16 to 42) – – – –
7 21.5±7.71 20.0 (0 to 37) –7.8±6.95 –6.0 (–31 to –3) <0.001 –
14 16.8±7.03 18.0 (2 to 31) –12.1±7.72 –11.0 (–32 to –2) <0.001 –14.514 to –9.765
21 15.3±7.34 16.0 (0 to 32) –13.6±8.70 –12.0 (–32 to –5) <0.001 –16.237 to –10.879
28 15.3±6.97 15.0 (0 to 33) –13.7±8.38 –12.0 (–32 to –4) <0.001 –16.231 to –11.071
MG-ADL 0 13.8±3.96 14.0 (6 to 20) – – – –
7 9.7±4.66 9.0 (0 to 19) –4.2±3.31 –4.0 (–14 to –3) <0.001 –5.223 to –3.158
14 7.6±4.15 7.0 (1 to 15) –6.2±3.87 –6.0 (–16 to –2) <0.001 –7.400 to –5.018
21 6.8±3.93 7.0 (0 to 13) –7.0±4.14 –6.0 (–16 to –3) <0.001 –8.252 to –5.702
28 6.8±3.81 6.0 (0 to 14) –7.0±4.41 –7.0 (–15 to –3) <0.001 –8.334 to –5.619
a Calculated from paired t test.
MG, myasthenia gravis; QMG, qualtitative MG test; MG-ADL, MG-activities of daily living.
–4.7
–6.4
–7.9 –7.8–7.8
–12.1
–13.6 –13.7
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–6
–3
0
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Fig. 2. Mean QMG, MG Composite, and MG-ADL change from Baseline by time point (evaluable population, 
n = 43, mean, SD). MG, myasthenia gravis; QMG, quantitative MG; MG-ADL, MG-activities of daily living.
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PLEX are comparably effective in adults with moderate 
to severe MG within 2 weeks of treatment [20]. An 
open-label study evaluating IVIG and PLEX in 87 sub-
jects with MG exacerbations also found no significant 
difference in efficacy; at Day 15, the mean change in 
Myasthenic Muscular Score was 15.6 (95% CI 10.9–
20.3) in the IVIG group and 16.6 (95% CI 11.6–21.6) in 
the PLEX group (p = 0.65) [11]. Another double-
blind  randomized trial comparing IVIG 2 g/kg with 
IVIG 1 g/kg for MG acute exacerbations in 173 subjects 
showed that the mean Myasthenic Muscular Score 
change in both IVIG dose groups was similar (effect 
size difference = 3.84; 95% CI –1.03 to 8.71; p = 0.12) 
[22, 26].
The present Phase 3 study was a single-arm clinical 
trial designed specifically to confirm the efficacy of 
IGIV-C 2 g/kg in MG exacerbations (≥ MGFA IVb se-
verity). Results were commensurate with improvements 
observed in randomized, controlled clinical trials of 
IVIG in MG worsening/MG exacerbations, and the 
magnitude of treatment effect was impactful and clini-
cally significant. The results of this study support IGIV-
C as treatment of severe MG exacerbations requiring 
hospitalization. 
The authors had full access to all the data in the study 
and take responsibility for the integrity of the data and the 
accuracy of the data analysis.
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Fig. 3. Proportion of respondersa assessed 
by QMG, MG Composite, and MG-ADL 
by time point (evaluable population, n = 
43). a Defined as at least a 3-point decrease 
for QMG and MG Composite and at least 
a 2-point decrease for MG-ADL from Base-
line to Day 14. MG, myasthenia gravis; 
QMG, quantitative MG; MG-ADL, MG-
Activities of Daily Living.
Table 3. Treatment-emergent AEs by subject irrespective of relationship to study drug (≥5% of subjects)
MedDRA system organ class and preferred term Subjects (n = 49), n (%) Events (n = 98), n (%)
Any treatment-emergent AE 39 (79.6) 98 (100.0)
Nervous system disorders 21 (42.9) 23 (23.5)
Headache 19 (38.8) 21 (21.4)
General disorders and administration site conditions 13 (26.5) 14 (14.3)
Pyrexia 8 (16.3) 9 (9.2)
Influenza like illness 3 (6.1) 3 (3.1)
Skin and subcutaneous tissue disorders 10 (20.4) 11 (11.2)
Urticaria 4 (8.2) 4 (4.1)
Rash 3 (6.1) 4 (4.1)
Gastrointestinal disorders 4 (8.2) 7 (7.1)
Vomiting 3 (6.1) 3 (3.1)
AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities.
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